SH5-07

    • Catalog No.:MC1371
    • Description
    • CasNo:
    • 1456632-41-9
    • MolecularFormula:
    • C29H28F5N3O5S
    • Purity:
    • >98%
    • Target:
    • STAT
    • IC50:
    • IC50: 3.9±0.6 μM (Stat3)[1]
    • In Vitro:
    • SH5-07 is a hydroxamic acid analog of BP-1-102. SH5-07 dose-dependently inhibits Stat3 activity with an IC50 of 3.9±0.6 μM in in vitro assay. It preferentially inhibits Stat3:Stat3 DNA-binding activity, ahead of inhibiting Stat1:Stat3 activity, with minimal effects on Stat1:Stat1 activity. SH5-07 binds Stat3, disrupts Stat3 association with growth factor receptor, and thereby inhibits Stat3 phosphorylation. It induces antitumor cell effects against malignant cells harboring constitutively-active Stat3. SH5-07 inhibits the expression of known Stat3-regulated genes. Bcl-2, Bcl-xL, c-Myc, Survivin, Cyclin D1 and Mcl-1 expression is reduced in response to 24 h, 5 μM SH5-07 treatment[1].
    • In Vivo:
    • Tail vein injection or oral gavage delivery of SH5-07 or SH4-54 inhibits growth of 90-150 mm3 established subcutaneous mouse xenografts of human glioma (U251MG) and breast (MDA-MB-231) tumors that harbor aberrantly-active Stat3, associated with decreased c-Myc, Mcl-1 and Cyclin D1 expression. No significant changes in body weights, blood cell counts, or the gross anatomy of organs, or obvious signs of toxicity are observed[1].
    • Fields:
    • SH5-07 is a hydroxamic acid based Stat3 inhibitor with an IC50 of 3.9±0.6 μM in in vitro assay.
    • Specificity:
    • Target: STAT. Fields: SH5-07 is a hydroxamic acid based Stat3 inhibitor with an IC50 of 3.9±0.6 μM in in vitro assay.
    • Dilution:
    • IC50: 3.9±0.6 μM (Stat3)[1]
    • Concentration:
    • >98%
    • Storage Stability:
    • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
    • Other Name:
    • SH-5-07; SH 5-07
    • MolecularWeight(Da):
    • 625.61
    • References:
    • [1]. Yue P,et al. Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res. 2016 Feb 1;76(3):652-63.
    • Products Images